Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Free Cash Flow (2016 - 2025)

Lisata Therapeutics' Free Cash Flow history spans 13 years, with the latest figure at -$3.2 million for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 28.25% year-over-year to -$3.2 million; the TTM value through Dec 2025 reached -$16.0 million, up 17.46%, while the annual FY2025 figure was -$16.0 million, 17.46% up from the prior year.
  • Free Cash Flow reached -$3.2 million in Q4 2025 per LSTA's latest filing, up from -$3.3 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$2.5 million in Q3 2024 to a low of -$8.2 million in Q1 2023.
  • Average Free Cash Flow over 3 years is -$4.6 million, with a median of -$4.1 million recorded in 2023.
  • Peak YoY movement for Free Cash Flow: increased 29.72% in 2024, then crashed 32.72% in 2025.
  • A 3-year view of Free Cash Flow shows it stood at -$4.1 million in 2023, then decreased by 11.28% to -$4.5 million in 2024, then grew by 28.25% to -$3.2 million in 2025.
  • Per Business Quant, the three most recent readings for LSTA's Free Cash Flow are -$3.2 million (Q4 2025), -$3.3 million (Q3 2025), and -$4.0 million (Q2 2025).